AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00871442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCEA solution (bupivacaine and fentanyl)
Description: PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
Study NCT02163616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 800 mcg of sublingual misoprostol
Study NCT03725033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subetta
Description: Oral administration.
Study NCT03725033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study NCT03896672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure will be applied three times daily during 7 consecutive days, if the physiotherapist follow the previous training. Each application should during 30 minutes. Pressure should be adjusted in 15 centimeters of water.
Study NCT02870842 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lung ultrasound
Description: Lung ultrasound on both hemithorax in supine position
Study NCT02870842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasound
Description: Lung ultrasound on both hemithorax in supine position
Study NCT02870842 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Respiratory management
Description: Appropriate respiratory managements depending on the lung ultrasound findings
Study NCT02870842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory management
Description: Appropriate respiratory managements depending on the lung ultrasound findings
Study NCT02745912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone/Bupropion
Description: Naltrexone/Bupropion extended-release tablets.
Study NCT02745912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin immediate-release tablet.
Study NCT00987402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain soap and water (PSW)
Description: Presence or absence of infection
Study NCT00987402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol-based hand rub (ABHR)
Description: Presence or absence of infection
Study NCT02333383 — intervention group
Intervention type: DRUG
Intervention: Adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection
Study NCT01941836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: Patients receive ETC-1002
Study NCT01941836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Patients receive ezetimibe
Study NCT01941836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Patients receive ezetimibe
Study NCT03408444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMO-114
Description: Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
Study NCT03408444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMO-116
Description: Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
Study NCT03408444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMO-118
Description: Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
Study NCT03408444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMO-117
Description: Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
Study NCT03135613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot at self-selected gait speed.
Study NCT03889119 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System.
Description: SBRT uses advanced imaging techniques to deliver targeted radiation to a tumor. The Elekta Versa and Agility Systems are approved by the Food and Drug Association (FDA) for SBRT treatment of cancer.
Study NCT03889119 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System.
Description: SBRT uses advanced imaging techniques to deliver targeted radiation to a tumor. The Elekta Versa and Agility Systems are approved by the Food and Drug Association (FDA) for SBRT treatment of cancer.
Study NCT00930631 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [3H] BMS747158
Description: Single bolus intravenous injection of \[3H\] BMS747158
Study NCT02174003 — intervention group
Intervention type: DEVICE
Intervention: High intensity whole-body infrared heating
Description: The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
Study NCT02452840 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT04268654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative Arterial Embolization
Description: PAE will be performed by arteriographic procedure before esophageal resection surgery minimum 14 days before surgery.~An angiogram of the celiac trunk is performed through a femoral access before and after the embolization. Embolization by coils of the left gastric artery, splenic artery and the right gastric artery is realized.
Study NCT03025568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK
Description: PEEK (poly-ether-ether-ketone) has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth. Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
Study NCT03025568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bre.flex
Description: In the recent time thermoplastic materials (breflex) become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus.
Study NCT03862768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Surgery requires at least removal of all drug-resistant lesions.
Study NCT03862768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 400 MG
Description: Imatinib 400 MG/d should be taken once the patients resume oral diet
Study NCT03862768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib escalation
Description: Imatinib 600 MG/d
Study NCT03862768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Sunitinib 37.5 MG/d
Study NCT00771511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capsaicin
Description: capsaicin cream 0.1% 10 ml applied to cervix
Study NCT00771511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Only lidocaine gel will be appled to the cervix
Study NCT00858507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RN Brief Intervention
Description: RN administered personal health assessment along with a brief intervention for behavior change administered to homeless veterans in the community
Study NCT00858507 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Social Worker Outreach
Description: Social worker will encounter homeless veteran in the community and encourage to come to the VA for care
Study NCT02164136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PANP-TME
Study NCT02164136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: O-PANP-TME
Study NCT01656486 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery that could produce a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland.
Study NCT00634426 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical excision of the metastatic process
Description: Surgical excision of the metastatic process
Study NCT00634426 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy of the metastatic spine process
Description: Standard of care radiotherapy for patients with metastatic epidural spinal cord compression.
Study NCT02856490 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vSculpt
Description: A genital vibration device that operates in two modes, vibration only or vibration and light, to help tone and tighten pelvic floor muscles.
Study NCT02856490 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InTone
Description: A genital device using electric muscle stimulation to treat incontinence.
Study NCT01013064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10760A or Placebo
Description: 0.04 mcg/kg to 2.0mcg/kg once intravenously
Study NCT03891641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadwell Tredlr
Description: Complete treadling exercise 3x per week (15 min sessions) for 6 weeks.
Study NCT04237623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: 250mcg/m2/day IV starting Day +5
Study NCT04237623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Arm
Description: Standard G-CSF given to those who decline to receive GM-CSF
Study NCT04284722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Perioperative continuation of oral metformin therapy according to the patient's normal dosage and dosage intervals
Study NCT04707456 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training operator
Description: After recruitment, the participants were divided into two groups to perform first-trimester ultrasound scan by two different levels of proficiency.~First group : operator has experience more than 3 years in NT scan and second trimester ultrasound scan Second group : operator has experience less than 3 years in NT scan and second trimester ultrasound scan
Study NCT01689467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Velvet Antler extract
Description: Fermented Velvet Antler extract (1g/day)
Study NCT01689467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1g/day)
Study NCT01675375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye Shield
Description: one application following refractive surgery
Study NCT04094831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: The intervention group will receive health education through CKD campaign and mHealth technology. During the half day CKD campaign, health education materials (leaflet and short textbook and recording notebook) will be provided to the study participants. A nephrologist will facilitate the campaign and contents (Annex-3) of the text book and leaflet (Annex-4) will be discussed. Important message from the text book (such as stage, risk factor, preventive measures) will be used to develop the leaflet. In addition,Basic health education information about CKD is included in the contents to help patients gain knowledge, awareness, and improve their behaviors. Discussion on basic kidney diseases, risk factors, and preventive measures of CKD is performing by CHWs over a mobile phone call to the study patients. The patients have the liberty to discuss their health-related issues with the CHWs over a period of 10 minutes
Study NCT02777242 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate auto-injector
Description: SC injections of QST 50 mg or 75 mg or 100 mg
Study NCT03143296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated reverberant environment
Description: Reverberant environments simulate real-life situations mimicking a living room, classroom and auditorium. Each simulation lasts up to 2 hours.
Study NCT03143296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulated reverberant environment
Description: Reverberant environments simulate real-life situations mimicking a living room, classroom and auditorium. Each simulation lasts up to 2 hours.
Study NCT02508779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bump2be
Description: Bump2be is an internet intervention focusing on six topics (called cores) psycho-educational in nature with the goals of improving individuals' ability to: a) anticipate extreme BG levels, b) detect the presence of extreme BG levels, c) address current extreme BG levels, and d) prevent future extreme BG levels. The program includes didactic information, self-assessment tools, and active learning exercises.
Study NCT02508779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Participants will continue to receive care from their clinician.
Study NCT03262155 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood test
Study NCT03212755 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum immunoglobulin G level
Description: measurement of the serum level as a marker of diabetic complications
Study NCT03212755 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: serum immunoglobulin G level
Description: measurement of the serum level as a marker of diabetic complications
Study NCT04518761 — intervention group
Intervention type: PROCEDURE
Intervention: Elective surgery
Description: Any patient who needs to undergo an elective surgery.
Study NCT01202669 — intervention group
Intervention type: OTHER
Intervention: No intervention planned, observational study only.
Description: No intervention planned, observational study only.
Study NCT05394883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise
Description: Women randomized to Supervised Exercise group will attend two to three exercise classes/week. Each session will consist of: 5-min flexibility warm-up and cool-down; 40 min of moderate intensity calculated as 40-59% Heart Rate Reserve (HRR) along with Rating of Perceived Exertion (RPE) between 13-14; and 20 minutes of resistance with an additional 30 minutes of unsupervised home aerobic activity per week. The women will be given their choice of aerobic equipment or walking either track/ treadmill to achieve a total of 40 minutes of moderate intensity exercise. The Supervised Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
Study NCT05394883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Exercise
Description: Women assigned to Home Exercise group will receive instructions for their home walking program including tips for walking indoors and outdoors, exercise handouts for warm-up/cool-down activities, demonstrations for resistance training activities and an exercise log. Women assigned to Home Exercise group will be contacted once per week to discuss their progress, barriers/challenges faced, ask questions, and strategies to achieve the exercise guidelines. The Home Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
Study NCT02735798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-302
Study NCT02735798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT01768741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic liver resection
Description: participants will be performed with laparoscopic hepatectomy using laparoscopic instruments
Study NCT01768741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open liver resection
Description: participants will be performed with open hepatectomy using laparotomic instruments
Study NCT02806817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-344
Description: ME-344 is a synthetic small molecule mitochondrial inhibitor based on the isoflavan ring structure. ME-344 is a chiral compound, and is manufactured predominantly as a single stereoisomer that is dextrorotatory. As a stereoisomeric drug with two chiral centers, ME-344 is one of four potential stereoisomers. The current manufacturing process produces a racemic mixture of two of those stereoisomers, which are enantiomers, and ME-344 is separated from the levorotatory enantiomer by chromatography in the final step.
Study NCT02806817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
Study NCT02806817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
Study NCT02806817 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Use saline as placebo
Study NCT01575483 — intervention group
Intervention type: DRUG
Intervention: No Intervention (subjects were previously treated with Onglyza®)
Description: No Intervention
Study NCT00825214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zapperclick
Description: Device deliveres small piezoelectrical discharge to bite site (forearm)
Study NCT00825214 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated zapperclick device
Description: placebo
Study NCT04620031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h
Study NCT04620031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Loading Dose：0.5 mg/kg, infused with 4 min ± 30 s~Maintenance Dose：Maintenance is started at 1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5 mg/kg/h. Range of maintenance dose:~0.3-4 mg/kg/h
Study NCT03927222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF
Description: 2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
Study NCT03927222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is a chemotherapy drug given to all enrolled patients at the post-RT clinic visit as dose-intensified TMZ (100 mg/m2/day for 21 days).
Study NCT03927222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus-Diphtheria Toxoid (Td)
Description: Before the first DC vaccination, patients will receive 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Prior to pp65 DC vaccination #4,(3±1) weeks after leukapheresis 2 the vaccine site will receive a pre-conditioning intradermal injection of Td (1 flocculation unit (Lf), in 0.3 mL of saline for a total of 0.4 mL).
Study NCT03927222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Granulocyte macrophage-colony stimulating factor (GM-CSF) is a sterile, white, preservative-free lyophilized powder in a vial containing 250 mcg that will be reconstituted in 0.5 mL of sterile water for injection and used as an adjuvant with the DC vaccine.
Study NCT03927222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 111-Indium-labeling of Cells for in vivo Trafficking Studies
Description: 111-In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs labeled with 111-In (50 μCi / 5 x 10\^7 DCs) and given i.d. as the fourth vaccine. In up to 16 patients, the fourth vaccine will be labeled with 111-In (50 μCi / 5 x 10\^7 DCs) prior to injection.